腎バイオマーカー市場：マーカータイプ、アッセイプラットフォームタイプ、アプリケーション、エンドユーザー別-2025-2030年世界予測

腎バイオマーカー市場は、2023年に13億3,000万米ドルと評価され、2024年には14億3,000万米ドルに達すると予測され、CAGR 7.72％で成長し、2030年には22億4,000万米ドルに達すると予測されています。

腎バイオマーカーは、腎機能および腎障害の検出に使用される重要な指標であり、腎疾患の早期診断およびモニタリングに非侵襲的な方法を提供します。腎バイオマーカーの必要性は、慢性腎臓病（CKD）や急性腎障害（AKI）の有病率の増加から生じており、早期発見により疾患の進行や患者の転帰を大きく変えることができます。これらのバイオマーカーは、臨床診断、医薬品開発、治療計画の個別化などに幅広く応用されています。最終用途は病院、診断研究所、研究機関など多岐にわたる。腎バイオマーカー市場に影響を与える主な成長要因としては、CKDや心血管疾患の増加、バイオマーカー研究の技術進歩、ヘルスケア支出の増加などが挙げられます。個別化医療に対する需要の急増と、バイオマーカー探索におけるAIベースのアナリティクスの統合は、大きなビジネスチャンスを浮き彫りにしています。企業は、継続的な研究開発、戦略的提携、製品ポートフォリオの拡大に投資することで、こうした進歩を活用し、市場の潜在力を効果的に取り込むことができます。

しかし、バイオマーカーの発見と検証にかかる高いコスト、規制上のハードル、標準化された手順の欠如など、いくつかの制約や課題によって市場の成長は制限されています。さらに、新興国では認知度やインフラが限定的であることも、さらなる課題となる可能性があります。イノベーションと研究に最適な分野としては、より特異度と感度の高い新規バイオマーカーの開発、包括的診断のためのマルチバイオマーカーパネルの探求、データ解析と予測能力を強化するためのバイオインフォマティクスとAI技術への投資などが挙げられます。市場の障壁を克服し、イノベーションを促進するために、研究者、バイオ医薬品企業、規制機関の間で協力的な取り組みが必要です。市場の競争は激しく、急速な進歩が特徴で、新たな科学的考察や技術開拓への継続的な適応が求められます。イノベーションで先行し、コストと効率の課題に取り組むことで、企業は成長を促進し、市場競争力を維持することができます。

市場力学：急速に進化する腎バイオマーカー市場の主要市場インサイトを公開

腎バイオマーカー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 人口における腎障害の有病率の上昇
  • 腎疾患および腎バイオマーカーに関する意識向上への取り組みの高まり
  • 個別化医薬品や標的療法の開発動向
• 市場抑制要因
  • 腎バイオマーカーに関連する高コスト
• 市場機会
  • 新しい腎バイオマーカーを導入するための活発な調査活動
  • 腎臓手術における新たな技術進歩
• 市場の課題
  • バイオマーカーの失敗に対する懸念

ポーターの5つの力：腎バイオマーカー市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：腎バイオマーカー市場における外部からの影響の把握

外部マクロ環境要因は、腎バイオマーカー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析腎バイオマーカー市場における競合情勢の把握

腎バイオマーカー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス腎バイオマーカー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、腎バイオマーカー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨腎バイオマーカー市場における成功への道筋を描く

腎バイオマーカー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 人口における腎疾患の有病率の上昇
    • 腎臓疾患に関する意識を高める取り組みの拡大と腎バイオマーカー
    • 個別化医薬品と標的療法の開発への傾向
  • 抑制要因
    • 腎バイオマーカーに関連する高コスト
  • 機会
    • 新しい腎バイオマーカーを導入するための強力な調査活動
    • 腎臓手術における新たな技術的進歩
  • 課題
    • バイオマーカーの失敗に対する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 腎バイオマーカー市場マーカータイプ別

• 血中尿素窒素
• クレアチニン
• シスタチンC
• 好中球ゼラチナーゼ関連リポカリン

第7章 腎バイオマーカー市場アッセイプラットフォームタイプ別

• 酵素アッセイ
• 酵素免疫測定法（ELISA）
• 比濁免疫測定法

第8章 腎バイオマーカー市場：用途別

• 診断と病気の進行のモニタリング
• 調査

第9章 腎バイオマーカー市場：エンドユーザー別

• 診断検査室
• 病院

第10章 南北アメリカの腎バイオマーカー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の腎バイオマーカー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの腎バイオマーカー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AstraZeneca PLC
• Bayer AG
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• BioPorto Diagnostics A/S
• Cipla Limited
• Danaher Corporation
• DiaSorin S.p.A.
• Eli Lilly and Co
• Enzo Biochem, Inc.
• Eurofins Viracor Inc.
• F. Hoffmann-La Roche Ltd.
• Fresenius Kabi AG
• Novartis AG
• Novatein Biosciences Inc.
• PerkinElmer Inc.
• Randox Laboratories Ltd.
• Renalytix AI PLC
• Sanofi-Aventis, LLC.
• Sekisui Diagnostics, LLC
• Siemens Healthineers AG
• SphingoTec GmbH
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. RENAL BIOMARKERS MARKET RESEARCH PROCESS
• FIGURE 2. RENAL BIOMARKERS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RENAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. RENAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. RENAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RENAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RENAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RENAL BIOMARKERS MARKET DYNAMICS
• TABLE 7. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY BLOOD UREA NITROGEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY CREATININE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY CYSTATIN C, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ENZYMATIC ASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY TURBIDIMETRIC IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY DIAGNOSIS & DISEASE PROGRESSION MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RENAL BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES RENAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. CHINA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. INDIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA RENAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. ITALY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. POLAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. QATAR RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY MARKER TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY ASSAY PLATFORM TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM RENAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. RENAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. RENAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

The Renal Biomarkers Market was valued at USD 1.33 billion in 2023, expected to reach USD 1.43 billion in 2024, and is projected to grow at a CAGR of 7.72%, to USD 2.24 billion by 2030.

Renal biomarkers are critical indicators used to detect kidney function and damage, offering a non-invasive method for early diagnosis and monitoring of renal diseases. The necessity for renal biomarkers arises from the growing prevalence of chronic kidney diseases (CKD) and acute kidney injuries (AKI), where early detection can significantly alter disease progression and patient outcomes. These biomarkers are applied extensively across clinical diagnostics, drug development, and personalizing treatment plans. The end-use spans across hospitals, diagnostic laboratories, and research institutions. Key growth factors influencing the renal biomarker market include the rising incidences of CKD and cardiovascular diseases, technological advancements in biomarker research, and increased healthcare expenditure. The burgeoning demand for personalized medicine and the integration of AI-based analytics in biomarker discovery highlight substantial opportunities. Companies can leverage these advancements by investing in continuous R&D, strategic collaborations, and expanding their product portfolios to capture the market potential effectively.

However, market growth is restricted by several limitations and challenging factors such as the high costs of biomarker discovery and validation, regulatory hurdles, and the lack of standardized procedures. Furthermore, limited awareness and infrastructure in emerging economies may pose additional challenges. The best areas for innovation and research include developing novel biomarkers with higher specificity and sensitivity, exploring multi-biomarker panels for comprehensive diagnosis, and investing in bioinformatics and AI technologies to enhance data analysis and prediction capabilities. There's a need for collaborative efforts between researchers, biopharma companies, and regulatory bodies to overcome market barriers and expedite innovation. The nature of the market is highly competitive, characterized by rapid advancements, and requires continuous adaptation to new scientific insights and technological developments. By staying ahead in innovation and addressing the challenges of cost and efficiency, businesses can drive growth and maintain a competitive edge in the renal biomarkers market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Renal Biomarkers Market

The Renal Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of renal disorders among population
  • Growing initiatives to create awareness on renal diseases and renal biomarkers
  • Trend towards developing personalized medicines and targeted therapies
• Market Restraints
  • High costs associated with renal biomarkers
• Market Opportunities
  • Robust research activities to introduce new renal biomarkers
  • Emerging technological advancements in renal surgeries
• Market Challenges
  • Concerns over failure of biomarkers

Porter's Five Forces: A Strategic Tool for Navigating the Renal Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Renal Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Renal Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Renal Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Renal Biomarkers Market

A detailed market share analysis in the Renal Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Renal Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Renal Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Renal Biomarkers Market

A strategic analysis of the Renal Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Renal Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Bio-Rad Laboratories, Inc., bioMerieux SA, BioPorto Diagnostics A/S, Cipla Limited, Danaher Corporation, DiaSorin S.p.A., Eli Lilly and Co, Enzo Biochem, Inc., Eurofins Viracor Inc., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Novartis AG, Novatein Biosciences Inc., PerkinElmer Inc., Randox Laboratories Ltd., Renalytix AI PLC, Sanofi-Aventis, LLC., Sekisui Diagnostics, LLC, Siemens Healthineers AG, SphingoTec GmbH, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Renal Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Marker Type, market is studied across Blood Urea Nitrogen, Creatinine, Cystatin C, and Neutrophil Gelatinase-Associated Lipocalin.
• Based on Assay Platform Type, market is studied across Enzymatic Assay, Enzyme-Linked Immunosorbent Assay (ELISA), and Turbidimetric Immunoassay.
• Based on Application, market is studied across Diagnosis & Disease Progression Monitoring and Research.
• Based on End-User, market is studied across Diagnostic Laboratories and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of renal disorders among population
    • 5.1.1.2. Growing initiatives to create awareness on renal diseases and renal biomarkers
    • 5.1.1.3. Trend towards developing personalized medicines and targeted therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with renal biomarkers
  • 5.1.3. Opportunities
    • 5.1.3.1. Robust research activities to introduce new renal biomarkers
    • 5.1.3.2. Emerging technological advancements in renal surgeries
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns over failure of biomarkers
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Renal Biomarkers Market, by Marker Type

• 6.1. Introduction
• 6.2. Blood Urea Nitrogen
• 6.3. Creatinine
• 6.4. Cystatin C
• 6.5. Neutrophil Gelatinase-Associated Lipocalin

7. Renal Biomarkers Market, by Assay Platform Type

• 7.1. Introduction
• 7.2. Enzymatic Assay
• 7.3. Enzyme-Linked Immunosorbent Assay (ELISA)
• 7.4. Turbidimetric Immunoassay

8. Renal Biomarkers Market, by Application

• 8.1. Introduction
• 8.2. Diagnosis & Disease Progression Monitoring
• 8.3. Research

9. Renal Biomarkers Market, by End-User

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Hospitals

10. Americas Renal Biomarkers Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Renal Biomarkers Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Renal Biomarkers Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AstraZeneca PLC
• 3. Bayer AG
• 4. Bio-Rad Laboratories, Inc.
• 5. bioMerieux SA
• 6. BioPorto Diagnostics A/S
• 7. Cipla Limited
• 8. Danaher Corporation
• 9. DiaSorin S.p.A.
• 10. Eli Lilly and Co
• 11. Enzo Biochem, Inc.
• 12. Eurofins Viracor Inc.
• 13. F. Hoffmann-La Roche Ltd.
• 14. Fresenius Kabi AG
• 15. Novartis AG
• 16. Novatein Biosciences Inc.
• 17. PerkinElmer Inc.
• 18. Randox Laboratories Ltd.
• 19. Renalytix AI PLC
• 20. Sanofi-Aventis, LLC.
• 21. Sekisui Diagnostics, LLC
• 22. Siemens Healthineers AG
• 23. SphingoTec GmbH
• 24. Thermo Fisher Scientific Inc.